Item 8.01. Other Events. On August 18, 2025, Iovance Biotherapeutics, Inc. issued a press release announcing the approval of Amtagvi® (lifileucel) in Canada for advanced melanoma after anti-PD-1 and targeted therapy. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. 99.1 Press Release of Iovance Biotherapeutics, Inc., dated August 18, 2025. ─────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded as Inline XBRL document) SIGNATURES